^
    6ms
    Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) (clinicaltrials.gov)
    P1, N=178, Recruiting, Merck Sharp & Dohme LLC | N=100 --> 178
    Enrollment change
    |
    Keytruda (pembrolizumab) • MK-1084 • MK-0472
    over1year
    Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) (clinicaltrials.gov)
    P1, N=100, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • MK-0472
    over1year
    Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • MK-0472